Inhaled lipid nanoparticles loaded with two medicines reduced IPF lung stiffness and fibrosis in mice, outperforming an ...
As an organ recipient, columnist Sam Kirton honors donors and their families each year by decorating holiday trees in the ...
Until then, my family chooses to remain thankful for the available PF treatments and hopeful about the advancements that are sure to come. A diagnosis of PF will change your life, but life is for the ...
The Pulmonary Fibrosis Foundation (PFF) Summit 2025 began for me with a nonstop flight from Washington, D.C., to Chicago during the longest government shutdown in the history of the U.S. I was ...
Treatment with Endeavor Biomedicines’ experimental oral therapy taladegib (ENV-101) improved lung function in people with idiopathic pulmonary fibrosis (IPF) in a Phase 2a clinical trial, newly ...
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).
Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...
BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...
Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback